1. Home
  2. YEXT vs ERAS Comparison

YEXT vs ERAS Comparison

Compare YEXT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yext Inc.

YEXT

Yext Inc.

HOLD

Current Price

$8.10

Market Cap

1.0B

Sector

Technology

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$3.48

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YEXT
ERAS
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
YEXT
ERAS
Price
$8.10
$3.48
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$9.44
$3.71
AVG Volume (30 Days)
1.0M
2.6M
Earning Date
12-08-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$447,666,000.00
N/A
Revenue This Year
$8.66
N/A
Revenue Next Year
$4.77
N/A
P/E Ratio
$13,993.17
N/A
Revenue Growth
9.46
N/A
52 Week Low
$5.51
$1.01
52 Week High
$9.20
$3.80

Technical Indicators

Market Signals
Indicator
YEXT
ERAS
Relative Strength Index (RSI) 36.25 58.02
Support Level $8.30 $3.32
Resistance Level $8.61 $3.77
Average True Range (ATR) 0.20 0.25
MACD -0.04 -0.03
Stochastic Oscillator 6.62 47.69

Price Performance

Historical Comparison
YEXT
ERAS

About YEXT Yext Inc.

Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: